Prediction of acute respiratory disease in current and former smokers with and without COPD

Russell P. Bowler; Victor Kim; Elizabeth Regan; André A.A. Williams; Stephanie A. Santorico; Barry J. Make; David A. Lynch; John E. Hokanson; George R. Washko; Peter Bercz; Xavier Soler; Nathaniel Marchetti; Gerard J. Criner; Joe Ramsdell; Mei Lan K. Han; Dawn Demeo; Antonio Anzueto; Alejandro Comellas; James D. Crapo; Mark Dransfield; J. Michael Wells; Craig P. Hersh; Neil MacIntyre; Fernando Martinez; Hrudaya P. Nath; Dennis Niewoehner; Frank Sciurba; Amir Sharafkhaneh; Edwin K. Silverman; Edwin J.R. Van Beek; Carla Wilson; Christine Wendt; Robert A. Wise; Jeffrey Curtis; Ella Kazerooni; Nicola Hanania; Philip Alapat; Venkata Bandi; Kalpalatha Guntupalli; Elizabeth Guy; William Lunn; Antara Mallampalli; Charles Trinh; Mustafa Atik; Francine Jacobson; R. Graham Barr; Byron Thomashow; John Austin; Lacey Washington; H. Page McAdams; Richard Rosiello; Timothy Bresnahan; Charlene McEvoy; Joseph Tashjian; Nadia Hansel; Robert Brown; Richard Casaburi; Janos Porszasz; Hans Fischer; Matt Budoff; Tadashi Allen; Kathryn Rice; Marilyn Foreman; Gloria Westney; Eugene Berkowitz; Adam Friedlander; Eleonora Meoni; Aditi Satti; A. James Mamary; Robert Steiner; Chandra Dass; William Bailey; Lynn Gerald; Paul Ferguson; Paul Friedman; Geoffrey McLennan; Edwin J.R. Van Beek; Deborah Thompson; Joel Weissfeld; Carl Fuhrman; Jessica Bon; Sandra Adams; Carlos Orozco; C. Santiago Restrepo; Amy Mumbower; Jonathan Samet; Amy Willis; Douglas Stinson; Terri Beaty; Barbara Klanderman; Nan Laird; Christoph Lange; Iuliana Ionita; Joyce Schroeder; John Newell; John Reilly; Harvey Coxson; Philip Judy; Eric Hoff Man; Raul San Jose Estepar; Rebecca Leek; Jordan Zach; Alex Kluiber; Anastasia Rodionova; Tanya Mann; Robert Crapo; Robert Jensen; Homayoon Farzadegan; James Murphy; Douglas Everett

doi:10.1378/chest.13-2946

Prediction of acute respiratory disease in current and former smokers with and without COPD

Russell P. Bowler, Victor Kim, Elizabeth Regan, André A.A. Williams, Stephanie A. Santorico, Barry J. Make, David A. Lynch, John E. Hokanson, George R. Washko, Peter Bercz, Xavier Soler, Nathaniel Marchetti, Gerard J. Criner, Joe Ramsdell, Mei Lan K. Han, Dawn Demeo, Antonio Anzueto, Alejandro Comellas, James D. Crapo, Mark DransfieldJ. Michael Wells, Craig P. Hersh, Neil MacIntyre, Fernando Martinez, Hrudaya P. Nath, Dennis Niewoehner, Frank Sciurba, Amir Sharafkhaneh, Edwin K. Silverman, Edwin J.R. Van Beek, Carla Wilson, Christine Wendt, Robert A. Wise, Jeffrey Curtis, Ella Kazerooni, Nicola Hanania, Philip Alapat, Venkata Bandi, Kalpalatha Guntupalli, Elizabeth Guy, William Lunn, Antara Mallampalli, Charles Trinh, Mustafa Atik, Francine Jacobson, R. Graham Barr, Byron Thomashow, John Austin, Lacey Washington, H. Page McAdams, Richard Rosiello, Timothy Bresnahan, Charlene McEvoy, Joseph Tashjian, Nadia Hansel, Robert Brown, Richard Casaburi, Janos Porszasz, Hans Fischer, Matt Budoff, Tadashi Allen, Kathryn Rice, Marilyn Foreman, Gloria Westney, Eugene Berkowitz, Adam Friedlander, Eleonora Meoni, Aditi Satti, A. James Mamary, Robert Steiner, Chandra Dass, William Bailey, Lynn Gerald, Paul Ferguson, Paul Friedman, Geoffrey McLennan, Edwin J.R. Van Beek, Deborah Thompson, Joel Weissfeld, Carl Fuhrman, Jessica Bon, Sandra Adams, Carlos Orozco, C. Santiago Restrepo, Amy Mumbower, Jonathan Samet, Amy Willis, Douglas Stinson, Terri Beaty, Barbara Klanderman, Nan Laird, Christoph Lange, Iuliana Ionita, Joyce Schroeder, John Newell, John Reilly, Harvey Coxson, Philip Judy, Eric Hoff Man, Raul San Jose Estepar, Rebecca Leek, Jordan Zach, Alex Kluiber, Anastasia Rodionova, Tanya Mann, Robert Crapo, Robert Jensen, Homayoon Farzadegan, James Murphy, Douglas Everett

Health Promotion Sciences

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

BACKGROUND: The risk factors for acute episodes of respiratory disease in current and former smokers who do not have COPD are unknown.

METHODS: Eight thousand two hundred forty-six non-Hispanic white and black current and former smokers in the Genetic Epidemiology of COPD (COPDGene) cohort had longitudinal follow-up (LFU) every 6 months to determine acute respiratory episodes requiring antibiotics or systemic corticosteroids, an ED visit, or hospitalization. Negative binomial regression was used to determine the factors associated with acute respiratory episodes. A Cox proportional hazards model was used to determine adjusted hazard ratios (HRs) for time to first episode and an acute episode of respiratory disease risk score.

RESULTS: At enrollment, 4,442 subjects did not have COPD, 658 had mild COPD, and 3,146 had moderate or worse COPD. Nine thousand three hundred three acute episodes of respiratory disease and 2,707 hospitalizations were reported in LFU (3,044 acute episodes of respiratory disease and 827 hospitalizations in those without COPD). Major predictors included acute episodes of respiratory disease in year prior to enrollment (HR, 1.20; 95% CI, 1.15-1.24 per exacerbation), airflow obstruction (HR, 0.94; 95% CI, 0.91-0.96 per 10% change in % predicted FEV 1 ), and poor health-related quality of life (HR, 1.07; 95% CI, 1.06-1.08 for each 4-unit increase in St. George's Respiratory Questionnaire score). Risks were similar for those with and without COPD.

CONCLUSIONS: Although acute episode of respiratory disease rates are higher in subjects with COPD, risk factors are similar, and at a population level, there are more episodes in smokers without COPD.

Original language	English (US)
Pages (from-to)	941-950
Number of pages	10
Journal	CHEST
Volume	146
Issue number	4
DOIs	https://doi.org/10.1378/chest.13-2946
State	Published - Oct 1 2014

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1378/chest.13-2946

Cite this

Bowler, R. P., Kim, V., Regan, E., Williams, A. A. A., Santorico, S. A., Make, B. J., Lynch, D. A., Hokanson, J. E., Washko, G. R., Bercz, P., Soler, X., Marchetti, N., Criner, G. J., Ramsdell, J., Han, M. L. K., Demeo, D., Anzueto, A., Comellas, A., Crapo, J. D., ... Everett, D. (2014). Prediction of acute respiratory disease in current and former smokers with and without COPD. CHEST, 146(4), 941-950. https://doi.org/10.1378/chest.13-2946

Bowler, RP, Kim, V, Regan, E, Williams, AAA, Santorico, SA, Make, BJ, Lynch, DA, Hokanson, JE, Washko, GR, Bercz, P, Soler, X, Marchetti, N, Criner, GJ, Ramsdell, J, Han, MLK, Demeo, D, Anzueto, A, Comellas, A, Crapo, JD, Dransfield, M, Wells, JM, Hersh, CP, MacIntyre, N, Martinez, F, Nath, HP, Niewoehner, D, Sciurba, F, Sharafkhaneh, A, Silverman, EK, Van Beek, EJR, Wilson, C, Wendt, C, Wise, RA, Curtis, J, Kazerooni, E, Hanania, N, Alapat, P, Bandi, V, Guntupalli, K, Guy, E, Lunn, W, Mallampalli, A, Trinh, C, Atik, M, Jacobson, F, Barr, RG, Thomashow, B, Austin, J, Washington, L, McAdams, HP, Rosiello, R, Bresnahan, T, McEvoy, C, Tashjian, J, Hansel, N, Brown, R, Casaburi, R, Porszasz, J, Fischer, H, Budoff, M, Allen, T, Rice, K, Foreman, M, Westney, G, Berkowitz, E, Friedlander, A, Meoni, E, Satti, A, Mamary, AJ, Steiner, R, Dass, C, Bailey, W, Gerald, L, Ferguson, P, Friedman, P, McLennan, G, Van Beek, EJR, Thompson, D, Weissfeld, J, Fuhrman, C, Bon, J, Adams, S, Orozco, C, Restrepo, CS, Mumbower, A, Samet, J, Willis, A, Stinson, D, Beaty, T, Klanderman, B, Laird, N, Lange, C, Ionita, I, Schroeder, J, Newell, J, Reilly, J, Coxson, H, Judy, P, Man, EH, Estepar, RSJ, Leek, R, Zach, J, Kluiber, A, Rodionova, A, Mann, T, Crapo, R, Jensen, R, Farzadegan, H, Murphy, J & Everett, D 2014, 'Prediction of acute respiratory disease in current and former smokers with and without COPD', CHEST, vol. 146, no. 4, pp. 941-950. https://doi.org/10.1378/chest.13-2946

@article{7d28999055354009afdd8f3f599d09d3,

title = "Prediction of acute respiratory disease in current and former smokers with and without COPD",

abstract = "BACKGROUND: The risk factors for acute episodes of respiratory disease in current and former smokers who do not have COPD are unknown.METHODS: Eight thousand two hundred forty-six non-Hispanic white and black current and former smokers in the Genetic Epidemiology of COPD (COPDGene) cohort had longitudinal follow-up (LFU) every 6 months to determine acute respiratory episodes requiring antibiotics or systemic corticosteroids, an ED visit, or hospitalization. Negative binomial regression was used to determine the factors associated with acute respiratory episodes. A Cox proportional hazards model was used to determine adjusted hazard ratios (HRs) for time to first episode and an acute episode of respiratory disease risk score.RESULTS: At enrollment, 4,442 subjects did not have COPD, 658 had mild COPD, and 3,146 had moderate or worse COPD. Nine thousand three hundred three acute episodes of respiratory disease and 2,707 hospitalizations were reported in LFU (3,044 acute episodes of respiratory disease and 827 hospitalizations in those without COPD). Major predictors included acute episodes of respiratory disease in year prior to enrollment (HR, 1.20; 95% CI, 1.15-1.24 per exacerbation), airflow obstruction (HR, 0.94; 95% CI, 0.91-0.96 per 10% change in % predicted FEV 1 ), and poor health-related quality of life (HR, 1.07; 95% CI, 1.06-1.08 for each 4-unit increase in St. George's Respiratory Questionnaire score). Risks were similar for those with and without COPD.CONCLUSIONS: Although acute episode of respiratory disease rates are higher in subjects with COPD, risk factors are similar, and at a population level, there are more episodes in smokers without COPD.",

author = "Bowler, {Russell P.} and Victor Kim and Elizabeth Regan and Williams, {Andr{\'e} A.A.} and Santorico, {Stephanie A.} and Make, {Barry J.} and Lynch, {David A.} and Hokanson, {John E.} and Washko, {George R.} and Peter Bercz and Xavier Soler and Nathaniel Marchetti and Criner, {Gerard J.} and Joe Ramsdell and Han, {Mei Lan K.} and Dawn Demeo and Antonio Anzueto and Alejandro Comellas and Crapo, {James D.} and Mark Dransfield and Wells, {J. Michael} and Hersh, {Craig P.} and Neil MacIntyre and Fernando Martinez and Nath, {Hrudaya P.} and Dennis Niewoehner and Frank Sciurba and Amir Sharafkhaneh and Silverman, {Edwin K.} and {Van Beek}, {Edwin J.R.} and Carla Wilson and Christine Wendt and Wise, {Robert A.} and Jeffrey Curtis and Ella Kazerooni and Nicola Hanania and Philip Alapat and Venkata Bandi and Kalpalatha Guntupalli and Elizabeth Guy and William Lunn and Antara Mallampalli and Charles Trinh and Mustafa Atik and Francine Jacobson and Barr, {R. Graham} and Byron Thomashow and John Austin and Lacey Washington and McAdams, {H. Page} and Richard Rosiello and Timothy Bresnahan and Charlene McEvoy and Joseph Tashjian and Nadia Hansel and Robert Brown and Richard Casaburi and Janos Porszasz and Hans Fischer and Matt Budoff and Tadashi Allen and Kathryn Rice and Marilyn Foreman and Gloria Westney and Eugene Berkowitz and Adam Friedlander and Eleonora Meoni and Aditi Satti and Mamary, {A. James} and Robert Steiner and Chandra Dass and William Bailey and Lynn Gerald and Paul Ferguson and Paul Friedman and Geoffrey McLennan and {Van Beek}, {Edwin J.R.} and Deborah Thompson and Joel Weissfeld and Carl Fuhrman and Jessica Bon and Sandra Adams and Carlos Orozco and Restrepo, {C. Santiago} and Amy Mumbower and Jonathan Samet and Amy Willis and Douglas Stinson and Terri Beaty and Barbara Klanderman and Nan Laird and Christoph Lange and Iuliana Ionita and Joyce Schroeder and John Newell and John Reilly and Harvey Coxson and Philip Judy and Man, {Eric Hoff} and Estepar, {Raul San Jose} and Rebecca Leek and Jordan Zach and Alex Kluiber and Anastasia Rodionova and Tanya Mann and Robert Crapo and Robert Jensen and Homayoon Farzadegan and James Murphy and Douglas Everett",

note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Kim has participated in clinical trials sponsored by Boehringer-Ingelheim, GlaxoSmithKline, MedImmune, and Roche Pharmaceuticals. Dr Make has participated in advisory boards for AstraZeneca; Boehringer-Ingelheim; GlaxoSmithKline; Pfizer Inc; Sunovion Pharmaceuticals Inc; Forest Pharmaceuticals, Inc; Merck; Ikaria; Philips Respironics; Aerocrine; Theravance, Inc; and Covidien Ltd. Dr Lynch is a consultant to Perceptive Imaging, Inc; Boehringer-Ingelheim; Genentech; Gilead Sciences, Inc; Veracyte; Intermune; and MedImmune. Dr Han has participated in research sponsored by GlaxoSmithKline with monies paid to her institution. She has consulted for GlaxoSmithKline, MedImmune, and Ikaria and has participated on speakers bureaus for GlaxoSmithKline; Boehringer-Ingelheim; Pfizer Inc; Forest Pharmaceuticals, Inc; Novartis; and Grifols. Dr Comellas has consulted for Vida Diagnostics, Inc. Dr Dransfield has served as a consultant for GlaxoSmithKline, Boehringer-Ingelheim, and Ikaria. His institution has received research grant support from the National Heart, Lung and Blood Institute; GlaxoSmithKline; and Forest Pharmaceuticals, Inc; and has received contracted support for enrollment in clinical trials from Aeris Therapeutics; Boehringer-Ingelheim; Boston Scientific; Centocor Ortho Biotech, Inc; GlaxoSmithKline; Forest Pharmaceuticals, Inc; Otsuka America Pharmaceutical, Inc; Pearl Therapeutics; Pfizer Inc; and Pulmonx. Dr Hersh has received lecture fees from Novartis and has served as a consultant to CSL Behring. Dr MacIntyre has received NIH funding for the COPDGene project. Dr Martinez has participated in steering committees in COPD or idiopathic pulmonary fibrosis sponsored by Actelion Pharmaceuticals Ltd; Bayer; Centocor Ortho Biotech, Inc; Forest Pharmaceuticals, Inc; Gilead Sciences, Inc; Jannsen Pharmaceuticals, Inc; GlaxoSmithKline, Nycomed/Takeda; and Promedior. He has participated in advisory boards for COPD or idiopathic pulmonary fibrosis for Amgen; AstraZeneca; Carden Jennings Publishing Co, Ltd; CardioMEMS; CSA Medical Inc; Forest Pharmaceuticals, Inc; Ikaria; Jannsen Pharmaceuticals, Inc; MedImmune; Merck; Pearl Therapeutics; Nycomed/Takeda; Pfizer Inc; and Vertex. Dr Martinez has participated on data safety monitoring committees sponsored by GlaxoSmithKline and Stromedix Inc. He has helped with Food and Drug Administration presentations for Boehringer-Ingelheim, GlaxoSmithKline, and Ikaria. He has spoken on COPD for Bayer; Forest Pharmaceuticals, Inc; GlaxoSmithKline; Nycomed/Takeda; and Prescott Medical Communications Group. He has participated in advisory teleconferences sponsored by the American Institute for Research, Axon, Cory Path, Grey Healthcare Group, Merion, and Sudler & Hennessey. He has received royalties from Informa Healthcare. Dr Niewoehner has received fees from Boehringer-Ingelheim, Novartis, and GlaxoSmithKline for serving on end point committees of clinical trials. He has received fees from AstraZeneca and Gilead Sciences, Inc, for serving on advisory boards. Dr Sciurba has served as a pharmaceutical consultant. Dr Silverman has received grant support from GlaxoSmithKline for studies of COPD genetics. Drs Bowler, Regan, Willams, Santorico, Hokanson, Washko, Bercz, Soler, Marchetti, Criner, Ramsdell, Demeo, Anzueto, Crapo, Wells, Nath, Sharafkhaneh, van Beek, Wendt, and Wise, and Ms Wilson have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Publisher Copyright: {\textcopyright} 2014 American College of Chest Physicians.",

year = "2014",

month = oct,

day = "1",

doi = "10.1378/chest.13-2946",

language = "English (US)",

volume = "146",

pages = "941--950",

journal = "Diseases of the chest",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "4",

}

TY - JOUR

T1 - Prediction of acute respiratory disease in current and former smokers with and without COPD

AU - Bowler, Russell P.

AU - Kim, Victor

AU - Regan, Elizabeth

AU - Williams, André A.A.

AU - Santorico, Stephanie A.

AU - Make, Barry J.

AU - Lynch, David A.

AU - Hokanson, John E.

AU - Washko, George R.

AU - Bercz, Peter

AU - Soler, Xavier

AU - Marchetti, Nathaniel

AU - Criner, Gerard J.

AU - Ramsdell, Joe

AU - Han, Mei Lan K.

AU - Demeo, Dawn

AU - Anzueto, Antonio

AU - Comellas, Alejandro

AU - Crapo, James D.

AU - Dransfield, Mark

AU - Wells, J. Michael

AU - Hersh, Craig P.

AU - MacIntyre, Neil

AU - Martinez, Fernando

AU - Nath, Hrudaya P.

AU - Niewoehner, Dennis

AU - Sciurba, Frank

AU - Sharafkhaneh, Amir

AU - Silverman, Edwin K.

AU - Van Beek, Edwin J.R.

AU - Wilson, Carla

AU - Wendt, Christine

AU - Wise, Robert A.

AU - Curtis, Jeffrey

AU - Kazerooni, Ella

AU - Hanania, Nicola

AU - Alapat, Philip

AU - Bandi, Venkata

AU - Guntupalli, Kalpalatha

AU - Guy, Elizabeth

AU - Lunn, William

AU - Mallampalli, Antara

AU - Trinh, Charles

AU - Atik, Mustafa

AU - Jacobson, Francine

AU - Barr, R. Graham

AU - Thomashow, Byron

AU - Austin, John

AU - Washington, Lacey

AU - McAdams, H. Page

AU - Rosiello, Richard

AU - Bresnahan, Timothy

AU - McEvoy, Charlene

AU - Tashjian, Joseph

AU - Hansel, Nadia

AU - Brown, Robert

AU - Casaburi, Richard

AU - Porszasz, Janos

AU - Fischer, Hans

AU - Budoff, Matt

AU - Allen, Tadashi

AU - Rice, Kathryn

AU - Foreman, Marilyn

AU - Westney, Gloria

AU - Berkowitz, Eugene

AU - Friedlander, Adam

AU - Meoni, Eleonora

AU - Satti, Aditi

AU - Mamary, A. James

AU - Steiner, Robert

AU - Dass, Chandra

AU - Bailey, William

AU - Gerald, Lynn

AU - Ferguson, Paul

AU - Friedman, Paul

AU - McLennan, Geoffrey

AU - Van Beek, Edwin J.R.

AU - Thompson, Deborah

AU - Weissfeld, Joel

AU - Fuhrman, Carl

AU - Bon, Jessica

AU - Adams, Sandra

AU - Orozco, Carlos

AU - Restrepo, C. Santiago

AU - Mumbower, Amy

AU - Samet, Jonathan

AU - Willis, Amy

AU - Stinson, Douglas

AU - Beaty, Terri

AU - Klanderman, Barbara

AU - Laird, Nan

AU - Lange, Christoph

AU - Ionita, Iuliana

AU - Schroeder, Joyce

AU - Newell, John

AU - Reilly, John

AU - Coxson, Harvey

AU - Judy, Philip

AU - Man, Eric Hoff

AU - Estepar, Raul San Jose

AU - Leek, Rebecca

AU - Zach, Jordan

AU - Kluiber, Alex

AU - Rodionova, Anastasia

AU - Mann, Tanya

AU - Crapo, Robert

AU - Jensen, Robert

AU - Farzadegan, Homayoon

AU - Murphy, James

AU - Everett, Douglas

N1 - Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Kim has participated in clinical trials sponsored by Boehringer-Ingelheim, GlaxoSmithKline, MedImmune, and Roche Pharmaceuticals. Dr Make has participated in advisory boards for AstraZeneca; Boehringer-Ingelheim; GlaxoSmithKline; Pfizer Inc; Sunovion Pharmaceuticals Inc; Forest Pharmaceuticals, Inc; Merck; Ikaria; Philips Respironics; Aerocrine; Theravance, Inc; and Covidien Ltd. Dr Lynch is a consultant to Perceptive Imaging, Inc; Boehringer-Ingelheim; Genentech; Gilead Sciences, Inc; Veracyte; Intermune; and MedImmune. Dr Han has participated in research sponsored by GlaxoSmithKline with monies paid to her institution. She has consulted for GlaxoSmithKline, MedImmune, and Ikaria and has participated on speakers bureaus for GlaxoSmithKline; Boehringer-Ingelheim; Pfizer Inc; Forest Pharmaceuticals, Inc; Novartis; and Grifols. Dr Comellas has consulted for Vida Diagnostics, Inc. Dr Dransfield has served as a consultant for GlaxoSmithKline, Boehringer-Ingelheim, and Ikaria. His institution has received research grant support from the National Heart, Lung and Blood Institute; GlaxoSmithKline; and Forest Pharmaceuticals, Inc; and has received contracted support for enrollment in clinical trials from Aeris Therapeutics; Boehringer-Ingelheim; Boston Scientific; Centocor Ortho Biotech, Inc; GlaxoSmithKline; Forest Pharmaceuticals, Inc; Otsuka America Pharmaceutical, Inc; Pearl Therapeutics; Pfizer Inc; and Pulmonx. Dr Hersh has received lecture fees from Novartis and has served as a consultant to CSL Behring. Dr MacIntyre has received NIH funding for the COPDGene project. Dr Martinez has participated in steering committees in COPD or idiopathic pulmonary fibrosis sponsored by Actelion Pharmaceuticals Ltd; Bayer; Centocor Ortho Biotech, Inc; Forest Pharmaceuticals, Inc; Gilead Sciences, Inc; Jannsen Pharmaceuticals, Inc; GlaxoSmithKline, Nycomed/Takeda; and Promedior. He has participated in advisory boards for COPD or idiopathic pulmonary fibrosis for Amgen; AstraZeneca; Carden Jennings Publishing Co, Ltd; CardioMEMS; CSA Medical Inc; Forest Pharmaceuticals, Inc; Ikaria; Jannsen Pharmaceuticals, Inc; MedImmune; Merck; Pearl Therapeutics; Nycomed/Takeda; Pfizer Inc; and Vertex. Dr Martinez has participated on data safety monitoring committees sponsored by GlaxoSmithKline and Stromedix Inc. He has helped with Food and Drug Administration presentations for Boehringer-Ingelheim, GlaxoSmithKline, and Ikaria. He has spoken on COPD for Bayer; Forest Pharmaceuticals, Inc; GlaxoSmithKline; Nycomed/Takeda; and Prescott Medical Communications Group. He has participated in advisory teleconferences sponsored by the American Institute for Research, Axon, Cory Path, Grey Healthcare Group, Merion, and Sudler & Hennessey. He has received royalties from Informa Healthcare. Dr Niewoehner has received fees from Boehringer-Ingelheim, Novartis, and GlaxoSmithKline for serving on end point committees of clinical trials. He has received fees from AstraZeneca and Gilead Sciences, Inc, for serving on advisory boards. Dr Sciurba has served as a pharmaceutical consultant. Dr Silverman has received grant support from GlaxoSmithKline for studies of COPD genetics. Drs Bowler, Regan, Willams, Santorico, Hokanson, Washko, Bercz, Soler, Marchetti, Criner, Ramsdell, Demeo, Anzueto, Crapo, Wells, Nath, Sharafkhaneh, van Beek, Wendt, and Wise, and Ms Wilson have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Publisher Copyright: © 2014 American College of Chest Physicians.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - BACKGROUND: The risk factors for acute episodes of respiratory disease in current and former smokers who do not have COPD are unknown.METHODS: Eight thousand two hundred forty-six non-Hispanic white and black current and former smokers in the Genetic Epidemiology of COPD (COPDGene) cohort had longitudinal follow-up (LFU) every 6 months to determine acute respiratory episodes requiring antibiotics or systemic corticosteroids, an ED visit, or hospitalization. Negative binomial regression was used to determine the factors associated with acute respiratory episodes. A Cox proportional hazards model was used to determine adjusted hazard ratios (HRs) for time to first episode and an acute episode of respiratory disease risk score.RESULTS: At enrollment, 4,442 subjects did not have COPD, 658 had mild COPD, and 3,146 had moderate or worse COPD. Nine thousand three hundred three acute episodes of respiratory disease and 2,707 hospitalizations were reported in LFU (3,044 acute episodes of respiratory disease and 827 hospitalizations in those without COPD). Major predictors included acute episodes of respiratory disease in year prior to enrollment (HR, 1.20; 95% CI, 1.15-1.24 per exacerbation), airflow obstruction (HR, 0.94; 95% CI, 0.91-0.96 per 10% change in % predicted FEV 1 ), and poor health-related quality of life (HR, 1.07; 95% CI, 1.06-1.08 for each 4-unit increase in St. George's Respiratory Questionnaire score). Risks were similar for those with and without COPD.CONCLUSIONS: Although acute episode of respiratory disease rates are higher in subjects with COPD, risk factors are similar, and at a population level, there are more episodes in smokers without COPD.

AB - BACKGROUND: The risk factors for acute episodes of respiratory disease in current and former smokers who do not have COPD are unknown.METHODS: Eight thousand two hundred forty-six non-Hispanic white and black current and former smokers in the Genetic Epidemiology of COPD (COPDGene) cohort had longitudinal follow-up (LFU) every 6 months to determine acute respiratory episodes requiring antibiotics or systemic corticosteroids, an ED visit, or hospitalization. Negative binomial regression was used to determine the factors associated with acute respiratory episodes. A Cox proportional hazards model was used to determine adjusted hazard ratios (HRs) for time to first episode and an acute episode of respiratory disease risk score.RESULTS: At enrollment, 4,442 subjects did not have COPD, 658 had mild COPD, and 3,146 had moderate or worse COPD. Nine thousand three hundred three acute episodes of respiratory disease and 2,707 hospitalizations were reported in LFU (3,044 acute episodes of respiratory disease and 827 hospitalizations in those without COPD). Major predictors included acute episodes of respiratory disease in year prior to enrollment (HR, 1.20; 95% CI, 1.15-1.24 per exacerbation), airflow obstruction (HR, 0.94; 95% CI, 0.91-0.96 per 10% change in % predicted FEV 1 ), and poor health-related quality of life (HR, 1.07; 95% CI, 1.06-1.08 for each 4-unit increase in St. George's Respiratory Questionnaire score). Risks were similar for those with and without COPD.CONCLUSIONS: Although acute episode of respiratory disease rates are higher in subjects with COPD, risk factors are similar, and at a population level, there are more episodes in smokers without COPD.

UR - http://www.scopus.com/inward/record.url?scp=84907942900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907942900&partnerID=8YFLogxK

U2 - 10.1378/chest.13-2946

DO - 10.1378/chest.13-2946

M3 - Article

C2 - 24945159

AN - SCOPUS:84907942900

VL - 146

SP - 941

EP - 950

JO - Diseases of the chest

JF - Diseases of the chest

SN - 0012-3692

IS - 4

ER -

Prediction of acute respiratory disease in current and former smokers with and without COPD

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this